Cassava Sciences Inc.
NEWS
Cassava Sciences has been informed by the Journal of Prevention of Alzheimer’s Disease that there is no evidence to support the charges, the company said Thursday.
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer’s disease.
The probe will be led by investigators experienced in determining whether or not entities have defrauded consumers, investors or government agencies.
The data used to support the argument that Aβ*56 is responsible for the Alzheimer’s Disease hallmark of memory loss appears to have been fabricated or heavily tampered with.
Cassava Sciences is reeling after another journal retracted an article co-authored by a key collaborator on its experimental Alzheimer’s disease therapeutic, simufilam.
Over the past several years, The Lone Star State has been growing in significance as a life sciences hub. Now the industry is flocking to Hays County and its Innovation Corridor.
Cassava Sciences CEO Remi Barbier is hitting back at The New York Times, calling out the newspaper for an article that he claims misrepresented the research of his company.
Shares of Cassava Sciences plunged after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam.
The FDA has not yet issued any hold orders to Cassava, but the company expects that its time is coming after rivals Denali and Cortexyme received theirs.
JOBS
IN THE PRESS